These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26340999)

  • 21. Navelbine: a new step in cancer therapy?
    Armand JP; Marty M
    Semin Oncol; 1989 Apr; 16(2 Suppl 4):41-5. PubMed ID: 2652319
    [No Abstract]   [Full Text] [Related]  

  • 22. A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine.
    Kirtane AR; Siegel RA; Panyam J
    J Pharm Sci; 2015 Mar; 104(3):1174-86. PubMed ID: 25583443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral/infusion cancer drug parity begins to raise health plan costs.
    Carroll J
    Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological research and precision cancer medicine: A call for manuscripts.
    Cho K; Clementi E; Levi-Schaffer F; Smalley KS; Radice S; Watts SW
    Pharmacol Res; 2015 Dec; 102():308-9. PubMed ID: 26542638
    [No Abstract]   [Full Text] [Related]  

  • 25. Biomarkers and personalized cancer medicine.
    Alers NI
    MLO Med Lab Obs; 2016 Feb; 48(2):18. PubMed ID: 26983295
    [No Abstract]   [Full Text] [Related]  

  • 26. Personalizing pancreatic cancer organoids with hPSCs.
    Zhang HC; Kuo CJ
    Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385
    [No Abstract]   [Full Text] [Related]  

  • 27. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 28. Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection.
    Dong Z; Zhang N; Li C; Wang H; Fang Y; Wang J; Zheng X
    BMC Cancer; 2015 Jun; 15():489. PubMed ID: 26121976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding barriers to drug delivery: high resolution in vivo imaging is key.
    Jain RK
    Clin Cancer Res; 1999 Jul; 5(7):1605-6. PubMed ID: 10430057
    [No Abstract]   [Full Text] [Related]  

  • 30. Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy.
    Shaker MA; Younes HM
    J Pharm Sci; 2009 Jul; 98(7):2268-98. PubMed ID: 19009549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs.
    Pal R; Berlow N
    Pac Symp Biocomput; 2012; ():351-62. PubMed ID: 22174290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of food effects for oral oncology drugs.
    Ratain MJ
    Clin Adv Hematol Oncol; 2012 Jun; 10(6):397-8. PubMed ID: 22895243
    [No Abstract]   [Full Text] [Related]  

  • 33. An introduction to stratified medicine.
    Greystoke A; Chaturvedi A
    Drug Discov Today; 2015 Dec; 20(12):1409-13. PubMed ID: 26253659
    [No Abstract]   [Full Text] [Related]  

  • 34. Let's talk about cytotoxic chemotherapy dosing: unravelling adjustments and off-protocol prescribing.
    Tjokrowidjaja A; Hovey E; Lewis CR
    Med J Aust; 2019 Feb; 210(2):65-66. PubMed ID: 30712300
    [No Abstract]   [Full Text] [Related]  

  • 35. Lack of access to targeted cancer therapy.
    Burki TK
    Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer chemotherapy.
    Satterwhite B
    Crit Care Update; 1981 Mar; 8(3):5-10. PubMed ID: 6907077
    [No Abstract]   [Full Text] [Related]  

  • 37. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
    Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Progress in the infusion technics].
    Munch Med Wochenschr; 1972 Dec; 114(50):2184-7. PubMed ID: 4678739
    [No Abstract]   [Full Text] [Related]  

  • 39. Disease progression in some cancers may be due to low blood levels of targeted therapies.
    Tuma RS
    J Natl Cancer Inst; 2008 Jul; 100(13):912-3. PubMed ID: 18577740
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanical approaches to oncological drug delivery.
    Carlisle R; Coussios CC
    Ther Deliv; 2013 Oct; 4(10):1213-5. PubMed ID: 24116903
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.